Radiolabeled regulatory peptides for imaging and therapy

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 1, 2010, Pages 69-76

  Nanda, Prasant K ^a   Lane, Stephanie R ^a,d   Retzloff, Lauren B ^a,d   Pandey, Usha S ^a   Smith, Charles Jeffrey ^a,b,c,d  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Molecular Pharmacology and Physiology ^*  (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

Molecular imaging; Peptides; Regulatory; Therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID AC 225; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE 3 OCTREOTIDE AC 225; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE 3 OCTREOTIDE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE 3 OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; BISMUTH 212; BISMUTH 213; COPPER 64; GALLIUM; GALLIUM 66; GALLIUM 67; GALLIUM 68; LUTETIUM 177; OCTREOTIDE; OCTREOTIDE[DEXTRO PHENYLALANYLCYSTEINYLPHENYLANINE DEXTRO TRYPTOPHYLLYSYLTHREONYLCYSTEINYLTHREONINE OL]; PEPTIDE; PEPTIDE RECEPTOR; RADIOISOTOPE; RADIOLABELED REGULATORY PEPTIDE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; TYROSINE 3 OCTREOTATE[DEXTRO PHENYLALANYLCYSTEINYLTYROSINE DEXTRO TRYPTOPHYLLYSYLTHREONYLCYSTEINYLTHREONINE]; TYROSINE 3 OCTREOTIDE[DEXTRO PHENYLALANYLCYSTEINYLTYROSINE DEXTRO TRYPTOPHYLLYSYLTHREONYLCYSTEINYLTHREONINE OL]; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 86; YTTRIUM 90;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CYCLOTRON; DIAGNOSTIC PROCEDURE; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; GAMMA SCINTIGRAPHY; HUMAN; ISOTOPE LABELING; METASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULAR IMAGING; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIMARY TUMOR; RADIATION INJURY; REVIEW; RISK FACTOR;

HUMANS; MOLECULAR IMAGING; NEOPLASMS; OLIGOPEPTIDES; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; RECEPTORS, MELANOCORTIN; RECEPTORS, PEPTIDE; RECEPTORS, SOMATOSTATIN;

EID: 75149157017     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833392ac     Document Type: Review

References (29)

1. Jong MD, Breeman WAP, Kwekkeboom DJ, et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res 2009; 42:873-880.
2. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008; 49:1735-1738.
3. Khan IU, Beck-Sickinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008; 8:186-199.
4. Miederer M, Henriksen G, Alke A, et al. Preclinical evaluation of the a-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008; 14:3555-3561.
5. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124-2130.
6. Muros MA, Varsavsky M, Rozas PI, et al. Outcome of treating advanced neuroendocrine tumors with radiolabeled somatostatin analogues. Clin Transl Oncol 2009; 11:48-53.
7. Wadas TJ, Eiblmaier M, Zheleznyak A, et al. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med 2008; 49:1819-1827.
8. Cescato R, Erchegyi J, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 2008; 51:4030-4037.
9. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008; 49:318-326.
10. Jensen RT, Battey JF, Spindel ER, et al. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008; 60:1-42.
11. Thomas R, Chen J, Roudier MM, et al. In vitro binding evaluation of 177Lu AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis 2009; 26:105-119.
12. Hoffman TJ, Smith CJ. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol 2009; 36:579-585.
13. Prasanphanich AF, Retzloff L, Lane SR, et al. In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7-14)NH2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 2009; 36:171-181.
14. Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47:1144-1152.
15. Schweinsberg C, Maes V, Brans L, et al. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjugate Chem 2008; 19:2432-2439.
16. Miao Y, Figueroa SD, Fisher DR, et al. 203Pb-labeled a-melanocyte- stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 2008; 49:823-829.
17. Cantorias MV, Figueroa SD, Quinn TP, et al. Development of high-specificactivity 68Ga-labeled DOTA-rhenium-cyclized a-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol 2009; 36:505-513.
18. Wie L, Zhang X, Gallazzi F, et al. Melanoma imaging using 111In-, 86Y-and 68Ga-labeled CHX-A00-Re(Arg11)CCMSH. Nucl Med Biol 2009; 36:345-354.
19. Miao Y, Gallazzi F, Guo H, Quinn TP. 111In-labeled lactam bridge-cyclized a-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjugate Chem 2008; 19:539-547.
20. Guo H, Shenoy N, Gershman BM, et al. Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized a-melanocyte-stimulating hormone peptide. Nucl Med Biol 2009; 36:267-276.
21. Raposinho PD, Xavier C, Correia JDG, et al. Melanoma targeting with amelanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. J Biol Inorg Chem 2008; 13:449-459.
22. Raposinho PD, Correia JDG, Alves S, et al. A 99mTc(CO)3-labeled pyrazolyl-amelanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol 2008; 35:91-99.
23. Bapst JP, Calame M, Tanner H, Eberle AN. Glycosylated DOTA-a-melanocyte-stimulating hormone analogues for melanoma targeting: influence of the site of glycosylation on in vivo biodistribution. Bioconjugate Chem 2009; 20:984-993.
24. Shi J, Kim YS, Zhai S, et al. Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjugate Chem 2009; 20:750-759.
25. Liu Z, Yan Y, Chin FT, et al. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009; 52:425-432.
26. Liu Z, Niu G, Wang F, Chen X. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009; 36:1483-1494.
27. Liu Z, Niu G, Shi J, et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin avb3 PET imaging. Eur J Nucl Med Mol Imaging 2009; 36:947-957.
28. Liu Z, Li ZB, CaoQ, et al. Small-animal PET of tumors with 64Cu-labeled RGDbombesin heterodimer. J Nucl Med 2009; 50:1168-1177.
29. Yang J, Guo H, Gallazzi F, et al. Evaluation of a novel Arg-Gly-Asp-conjugated a-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjugate Chem 2009; 20:1634-1642.